Clinical Nurse Specialist Advanced Pharmacology 2 — Questions and Answers
Question 1: A patient is receiving vancomycin for MRSA bacteremia. The pharmacy calls to report a vancomycin AUC/MIC of 350 mg·h/L (target 400-600 mg·h/L). What pharmacokinetic action should the CNS recommend?
- Decrease the vancomycin dose to reduce nephrotoxicity risk
- Increase the vancomycin dose or frequency to achieve target AUC/MIC ratio for optimal MRSA killing (Correct answer)
- Switch to an alternative antibiotic since the current target cannot be achieved
- Continue the same dose and recheck AUC in 5 days
Correct answer: Increase the vancomycin dose or frequency to achieve target AUC/MIC ratio for optimal MRSA killing
AUC/MIC of 350 is below the target of 400-600 mg·h/L — dose optimization is required for adequate bactericidal activity against MRSA while monitoring for nephrotoxicity.
ASHP/IDSA/SIDP 2020 vancomycin monitoring guidelines shifted from trough-only monitoring to AUC/MIC-guided dosing. Rationale: vancomycin is AUC/MIC-dependent (area under the concentration-time curve relative to MIC determines killing); AUC/MIC target for MRSA 400-600 mg·h/L (assumes MIC <=1 mg/L). Below target (AUC < 400): inadequate killing, risk of treatment failure, potential emergence of resistance. Above target (AUC > 600): increased nephrotoxicity risk. AUC calculation: Bayesian pharmacokinetic software (preferred) or two-level sampling. CNS action: collaborate with clinical pharmacist to dose-optimize (increase dose and/or frequency), recheck AUC after 2-3 doses, monitor SCr twice weekly. If MRSA MIC >=2 mg/L, consider alternative agents (daptomycin, linezolid, ceftaroline, televancin) as vancomycin may be inadequate regardless of dosing. Individualized, pharmacokinetically-guided vancomycin dosing is a key CNS competency in critical care.
Question 2: A patient with type 2 diabetes and eGFR 35 mL/min is on metformin 1000 mg twice daily. Which pharmacological recommendation is appropriate?
- Continue metformin at the current dose since eGFR 35 is above the absolute contraindication threshold
- Reduce metformin dose (maximum 1000 mg/day total) and monitor renal function every 3 months given eGFR 30-45 range (Correct answer)
- Discontinue metformin immediately and switch to insulin
- Increase metformin to maximum dose to improve glycemic control before renal function worsens
Correct answer: Reduce metformin dose (maximum 1000 mg/day total) and monitor renal function every 3 months given eGFR 30-45 range
FDA guidance: metformin is contraindicated at eGFR <30; at eGFR 30-45, use with caution at reduced doses with frequent renal monitoring — maximum 1000 mg/day total.
FDA 2016 revised metformin labeling (replacing previous serum creatinine thresholds): (1) eGFR >=45 mL/min: no restriction; (2) eGFR 30-44 mL/min: use caution, assess risks/benefits, reduce dose if initiated; maximum recommended dose varies by guideline — many experts recommend 500-1000 mg/day total; increase renal monitoring frequency (every 3 months); (3) eGFR <30 mL/min: CONTRAINDICATED (risk of metformin-associated lactic acidosis — MALA, rare but potentially fatal). Mechanism: metformin is renally cleared; accumulation in renal insufficiency inhibits mitochondrial complex I leading to increased anaerobic metabolism and lactic acid accumulation. Risk factors for MALA: dehydration, acute illness, contrast dye use. Hold metformin before contrast-enhanced studies in patients with CKD. This patient at eGFR 35 needs dose reduction, not discontinuation, with close monitoring.
Question 3: A patient develops acute ST-elevation MI (STEMI) and receives thrombolytic therapy with alteplase. Which pharmacological mechanism distinguishes alteplase from streptokinase?
- Alteplase is a direct thrombin inhibitor, while streptokinase activates plasminogen indirectly
- Alteplase is a recombinant tissue plasminogen activator (tPA) that is fibrin-selective, while streptokinase is a non-selective bacterial protein that causes systemic fibrinolysis (Correct answer)
- Streptokinase is more fibrin-selective and therefore has a lower bleeding risk than alteplase
- Both drugs have identical mechanisms but differ only in their half-lives
Correct answer: Alteplase is a recombinant tissue plasminogen activator (tPA) that is fibrin-selective, while streptokinase is a non-selective bacterial protein that causes systemic fibrinolysis
Alteplase (tPA) is fibrin-selective — it activates plasminogen preferentially at the clot surface; streptokinase causes systemic (non-selective) fibrinolysis with greater systemic bleeding risk.
Thrombolytic pharmacology: (1) Alteplase (rtPA): recombinant human tissue plasminogen activator; fibrin-selective — preferentially binds fibrin in clots, activates clot-bound plasminogen, producing plasmin for local clot lysis; shorter half-life (5 min), requires continuous infusion; no antigenicity (human protein); (2) Streptokinase: bacterial protein from Group C streptococci; forms a 1:1 complex with plasminogen causing activation of systemic plasminogen and systemic fibrinolysis that depletes fibrinogen, plasminogen, factors V/VIII; antigenic (causes anaphylaxis, neutralizing antibodies — cannot re-dose within 6-12 months); longer half-life; now rarely used in developed countries for STEMI; (3) Other tPA agents: tenecteplase (TNK-tPA, single IV bolus, high fibrin selectivity), reteplase (r-PA, two IV boluses). GUSTO trial showed alteplase superior to streptokinase for anterior STEMI. For STEMI, primary PCI is preferred over thrombolysis when available within 120 min of first medical contact.
Question 4: A patient is receiving heparin infusion post-cardioversion. New labs show: platelets 80,000/uL (down from 240,000/uL 5 days ago), positive PF4/heparin ELISA. The 4T score is 7. What is the most appropriate pharmacological action?
- Increase the heparin dose since the patient is potentially sub-therapeutic due to thrombocytopenia
- Immediately discontinue heparin and initiate a non-heparin anticoagulant (argatroban or fondaparinux) (Correct answer)
- Switch from unfractionated heparin to low-molecular-weight heparin
- Continue heparin and add a platelet transfusion for thrombocytopenia
Correct answer: Immediately discontinue heparin and initiate a non-heparin anticoagulant (argatroban or fondaparinux)
4T score 7 = high probability HIT; immediate heparin cessation and initiation of a non-heparin anticoagulant is essential — continued heparin causes catastrophic thrombosis.
Heparin-Induced Thrombocytopenia (HIT) Type II: (1) Pathophysiology: IgG antibodies against PF4/heparin complex that bind platelets via FcgammaRIIa leading to platelet activation, massive thrombin generation, and arterial and venous thrombosis (thrombocytopenia paradoxically causes thrombosis); (2) 4T Score (pre-test probability): Thrombocytopenia (>50% drop = 2 points), Timing (days 5-10 = 2 points), Thrombosis (new = 2 points), oTher cause (none = 2 points). Score 6-8 = high probability; (3) Management: STOP ALL heparin products (UFH, LMWH, heparin flushes); initiate non-heparin anticoagulant: argatroban (direct thrombin inhibitor, hepatic metabolism — preferred in renal failure) or fondaparinux (Xa inhibitor, limited evidence but used); bivalirudin alternative; (4) Do NOT: transfuse platelets (fuels thrombosis), switch to LMWH (cross-reactive antibodies); warfarin should not be started until platelet count recovers to >150,000 (risk of warfarin-induced skin necrosis/venous limb gangrene in HIT).
Question 5: A CNS is reviewing the pharmacological management of a patient with COPD exacerbation requiring bronchodilator therapy. Which statement about ipratropium and albuterol combination therapy is most accurate?
- Ipratropium and albuterol should not be combined because they cause opposing bronchodilation mechanisms
- The combination provides additive bronchodilation — ipratropium blocks muscarinic receptors, albuterol activates beta-2 receptors — through complementary mechanisms (Correct answer)
- Albuterol is sufficient for COPD exacerbations; ipratropium is only for chronic stable COPD management
- Ipratropium is preferred over albuterol in COPD because beta-2 receptors are absent in COPD airways
Correct answer: The combination provides additive bronchodilation — ipratropium blocks muscarinic receptors, albuterol activates beta-2 receptors — through complementary mechanisms
Ipratropium (anticholinergic) and albuterol (beta-2 agonist) have complementary mechanisms — both cause bronchodilation through different pathways, providing additive benefit in COPD exacerbation.
COPD bronchodilator pharmacology: (1) Albuterol (SABA — Short-Acting Beta-2 Agonist): activates beta-2-adrenergic receptors leading to adenylyl cyclase activation, increased cAMP, PKA activation, phosphorylation of myosin light chain kinase, and bronchial smooth muscle relaxation; onset 5 min, duration 4-6h; (2) Ipratropium (SAMA — Short-Acting Muscarinic Antagonist): blocks M3 muscarinic receptors on airway smooth muscle, preventing acetylcholine-mediated bronchoconstriction; particularly effective in COPD (cholinergic tone is dominant bronchoconstrictor pathway in COPD vs. asthma); onset 15-20 min, duration 4-6h; (3) Combination (DuoNeb): additive bronchodilation through two independent pathways; GOLD guidelines recommend combined short-acting bronchodilators for COPD exacerbations; (4) Beta-2 receptors are present in COPD airways — they are downregulated in severe asthma but not in COPD. The CNS ensures both agents are ordered for acute COPD exacerbation and that the combination product (ipratropium/albuterol nebulizer) is used appropriately.
Question 6: A patient receiving amiodarone for ventricular tachycardia develops new-onset dyspnea and bilateral pulmonary infiltrates on chest X-ray after 3 months of therapy. What is the most likely diagnosis and appropriate management?
- Community-acquired pneumonia; treat with antibiotics and continue amiodarone
- Amiodarone pulmonary toxicity (APT); discontinue amiodarone and initiate corticosteroid therapy (Correct answer)
- Amiodarone-induced thyrotoxicosis causing high-output cardiac failure and pulmonary edema
- New-onset CHF due to amiodarone's negative inotropic effects
Correct answer: Amiodarone pulmonary toxicity (APT); discontinue amiodarone and initiate corticosteroid therapy
Amiodarone pulmonary toxicity (APT) is a serious adverse effect (1-5% incidence); presents with dyspnea and bilateral infiltrates — requires drug discontinuation and often corticosteroids.
Amiodarone is highly effective for ventricular arrhythmias but has a significant adverse effect profile related to its high iodine content (37% by weight) and extreme tissue accumulation (t1/2 40-55 days): (1) Pulmonary toxicity (APT): 1-5% incidence; can occur at any time during therapy; presents with dyspnea, cough, fever, bilateral diffuse infiltrates on CXR; diagnosis: clinical plus imaging plus BAL showing foamy macrophages plus gallium scan uptake; treatment: DISCONTINUE amiodarone (essential), corticosteroids (prednisone 40-60 mg/day for 2-6 months) to suppress inflammatory component; prognosis generally good if caught early; (2) Thyroid: hypothyroidism (more common in iodine-sufficient countries, 6%) and thyrotoxicosis (type I = iodine excess, type II = destructive thyroiditis); check TFTs every 3-6 months; (3) Hepatotoxicity: LFTs every 6 months; (4) Monitoring requirements: baseline + annual CXR, PFTs, LFTs, TFTs, ophthalmology. The CNS ensures comprehensive amiodarone monitoring protocols are in place.
Clinical Nurse Specialist Advanced Pharmacology 2
A patient is receiving vancomycin for MRSA bacteremia.
The pharmacy calls to report a vancomycin AUC/MIC of 350 mg·h/L (target 400-600 mg·h/L).
What pharmacokinetic action should the CNS recommend?